Two groundbreaking cell-based gene therapies, exagamglogene autotemcel and lovotibeglogene autotemcel, were recently approved by the FDA for the treatment of sickle cell disease.
Krystle Imamura, PharmD Candidate
Advertisement
Articles by Krystle Imamura, PharmD Candidate
Advertisement
Latest Updated Articles
Advances in Sickle Cell Disease: New Gene Therapies and Management StrategiesPublished: September 16th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
2
Enhancing Early Cholesterol Detection and Management in Young Adults
3
Integrating Combination Therapies for Type 2 Diabetes and CKD
4
Building a Unified Approach to Cardio Kidney Metabolic Health
5
